BiPER Therapeutics
Description
BiPER Therapeutics is developing oral First In Class small molecules against cancer. BPR001-615 our lead clinical candidate, at 9 months from the clinic, pushes cancers cells to burn out - a unique mechanism of action.
We successfully closed our Seed financing at the end of 2022 and are currently in our Series A fundraising round to bring our first candidate up to clinical proof of concept. We are a seasoned team of biotech/pharma and academic experts (INSERM, CNRS) leveraging more than 10 years of extensively awarded research. Our portfolio of 7 patents includes 3 composition of matters and 4 patents of use.
BBPR001-615 is a first-in-class BiP inhibitor exhibiting strong anti-tumor Activity
- BPR001-615 clinical candidate demonstrated tumor growth inhibition > 70% in 3 solid tumors in vivo models
- BPR001-615 triggered > 75% tumor growth inhibition in gastric cancer model in a 70 days study
- BPR001-615 cured 4 mice over 10 and triggered 77% tumor growth inhibition in colorectal cancer model
- BPR001-615 demonstrated in excellent safety profile
BPR0001-615 has been developed to treat patients with high unmet medical needs by precision medicine approach
- BiP overexpression is correlated to poor prognosis of patients accross multiple cancer indications
- 50% of patients are BiP high across multiple cancer indications
- Precision medicine approach through measurement of BIP in patients’ plasma
- Phase 1/2a in early Q2 2025 to evaluate tolerability and preliminary efficacy of BPR001-615 in R/R patients with Gastro-intestinal cancers (Gastric and Esophageal, Colorectal, Pancreatic Cancers) and solid tumors
- Priority to indication Gastric Cancer indication in Phase 2b for which Orphan Drug Designation is ongoing (1 Million Cases – 4 Billions $ Global Sales forecast @2029 horizon )
Company members
Co-founders Mehdi Chelbi - Stephane Rocchi - Rachid Benhida - Cyril Ronco
